Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2015 12:52 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces Termination of Public Offering

MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
May 06, 2015 10:14 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial

MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
May 01, 2015 08:56 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces Pricing of $25 Million Public Offering

MALVERN, Pa., May 1, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
April 30, 2015 16:01 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces Public Offering of Common Stock

MALVERN, Pa., April 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
April 21, 2015 08:00 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B

MALVERN, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
April 20, 2015 08:00 ET | Source: TetraLogic Pharmaceuticals

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors

MALVERN, Pa. and KENILWORTH, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and...
April 09, 2015 10:11 ET | Source: TetraLogic Pharmaceuticals

TetraLogic to Present at the 14th Annual Needham Healthcare Conference

MALVERN, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...
February 26, 2015 16:10 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update

MALVERN, Pa., Feb. 26, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
December 18, 2014 07:00 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma

MALVERN, Pa., Dec. 18, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with...
December 16, 2014 07:00 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Provides Update on Ovarian Cancer Study

MALVERN, Pa., Dec. 16, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right